[go: up one dir, main page]

WO2014069677A1 - Inhibition de la mélanogenèse par l'huile de café extraite par co2 supercritique - Google Patents

Inhibition de la mélanogenèse par l'huile de café extraite par co2 supercritique Download PDF

Info

Publication number
WO2014069677A1
WO2014069677A1 PCT/KR2012/008909 KR2012008909W WO2014069677A1 WO 2014069677 A1 WO2014069677 A1 WO 2014069677A1 KR 2012008909 W KR2012008909 W KR 2012008909W WO 2014069677 A1 WO2014069677 A1 WO 2014069677A1
Authority
WO
WIPO (PCT)
Prior art keywords
melanogenesis
coffee
coffee oil
oil
inhibitory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/008909
Other languages
English (en)
Inventor
Sangyo BYUN
Youngkeun SONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajou University Industry Academic Cooperation Foundation
Original Assignee
Ajou University Industry Academic Cooperation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajou University Industry Academic Cooperation Foundation filed Critical Ajou University Industry Academic Cooperation Foundation
Priority to PCT/KR2012/008909 priority Critical patent/WO2014069677A1/fr
Publication of WO2014069677A1 publication Critical patent/WO2014069677A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/742—Coffea, e.g. coffee
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine

Definitions

  • the present invention relates to the inhibitory melanogenesis of coffee oil extracted by supercritical carbon dioxide.
  • This coffee oil is useful for skin whitening by inhibition the early period of melanogenesis which was proved by the down-regulation of 8 identified proteins including -MSH, MC1R, ACTHR, MITF, PKC-, SCF, TYR and TRP-2.
  • Robusta ( Coffea Robusta ) is a species of coffee which has its origins in central and western sub-Saharan Africa and was introduced into Southeast Asia by French colonists in the late 19th century. According to the statistics of the International Coffee Organization, approximately one-third of the coffee produced in the world is Robusta, and Vietnam has been the world's single largest exporter of Robusta in recent years.
  • Chlorogenic acids are a family of esters formed between trans-cinnamic acids and quinic acid. The commonest individual chlorogenic acid is formed between caffeic acid and quinic acid. It has been shown that both chlorogenic acid and caffeic acid are strong antioxidants in vitro. Coffee beans are one of the richest dietary sources of chlorogenic acid and for many consumers this will be their major dietary source. The roasting of coffee beans dramatically increases their total antioxidant activity. A roasting time of 10 minutes (medium-dark roast) was found to produce coffee with optimal oxygen scavenging and chain breaking activities in vitro.
  • coffee has significantly more total antioxidant activity than either cocoa, green tea, black tea or herbal tea. It can be concluded that coffee possesses greater in-vitro antioxidant activity than other beverages, due in part to intrinsic compounds such as chlorogenic acid, in part to compounds formed during roasting such as melanoidins and in part to as yet unidentified compounds.
  • the melanogenesis is a process of production of special pigment in our body called melanin.
  • Human epidermis contains special cells - melanocytes - which are responsible for melanogenesis. And the amount of melanin in human epidermis defines the skin color.
  • the synthesis and distribution of melanin in the epidermis involves several steps: transcription of melanogenic proteins, melanosome biogenesis, sorting of melanogenic proteins into the melanosomes, transport of melanosomes to the tips of melanocytes dendrites and finally transfer into keratinocytes.
  • Melanin formation and transformation in human skin is an important mechanism for the protection of skin from the UV light. Side effects like hypopigmentation or hyperpigmentation can occur due to numerical mutations.
  • MC1R activates the cyclic AMP (cAMP) response-element binding protein (CREB).
  • cAMP cyclic AMP
  • CREB cyclic AMP response-element binding protein
  • TRP1 tyrosinase-related protein 1
  • TRP2 dopachrome tautomerase
  • An invention was carried out to evaluate the skin whitening efficacy of Vietnamese Robusta oil.
  • Vietnamese Robusta green beans were roasted at six different levels and extracted oil by supercritical carbon dioxide. After measuring the radical scavenging activity and tyrosinase inhibition activity of coffee oils, the good roasting condition was chosen for in vitro test on B16F1 mouse melanoma cells.
  • MTT assay was conducted to identify the toxicity of the coffee oil. After that, melanin content was measured to evaluate the inhibition of Vietnamese Robusta oil on melanin production.
  • proteome analysis using 2-D was conducted to observe the changes of proteins that are involved in melanogenesis.
  • Coffee oil was found to inhibite well melanogenesis of mouse melanoma B16F1cells. Coffee at roasting level 4 (230, 15min) has stronger melanogenesis inhibition activity with SC50 value for DPPH scavenging is 400 mg/L and IC50 value for Tyrosinase Inhibiton is 17.73 mg/L. Melanin content of melanoma cells treated with 10 mg/L VN Robusta oil decrease about 25%. The coffee oil inhibits the early period of melanogenesis is which was proved by the down-regulation of 8 identified proteins including -MSH, MC1R, ACTHR, MITF, PKC-, SCF, TYR and TRP-2.
  • Fig. 1. is a bar chart showing the IC50 (mg/L) of Tyrosinase Inhibition Activity of the coffee oils. Oils extracted from 3 roasting levels 4 (230, 15min), 5 (250, 15min) and 6 (250, 20min) were tested for tyrosinase inhibition activity. The IC50 of the coffee oils were calculated. At every roasting level, the tyrosinase inhibition activity of coffee oil is in concentration dependent manner. Following the roasting levels from 4 to 6, the tyrosinase inhibition properties of the coffee oil decreased regularly. Base on the IC50 values, the coffee oil at roasting level 4 was chosen as the efficient condition.
  • Fig. 2. is a graph showing the Melanin content (%) in Melanoma B16F1 treated by the coffee oil.
  • the melanin contents formed inside and released outside of the cells treated by the coffee oil at 0.1; 0.5; 1; 5 and 10 mg/L were measured. The higher concentration of oil treated, the lower intracellular and extracellular melanin contents were. At 10 mg/L of treating oil, the total melanin content was decreased over 25%. This proved that the coffee oil had the ability to inhibit melanin production in melanoma cells.
  • Fig. 3. is a 2D-PAGE images of proteins extracted from melanoma B16F1 treated by 10 mg/L of the coffee oil at roasting level 4.
  • the left image is control, and the right image if the 2D-PAGE image of melanoma treated with the coffee oil.
  • the changes of melanogenesis related proteins were observed by comparing the control 2-D gel and sample 2-D gel which was treated by 10 mg/L of the coffee oil at roasting level 4.
  • On control gel and sample gel there were 625 and 666 detected spots respectively. Among them, 398 spots were matched in which 186 spots were up-regulated and 212 spots were down-regulated. Base on isoelectric point (pI) and molecular weight (MW), 8 proteins were identified.
  • pI isoelectric point
  • MW molecular weight
  • MSH melanocortin 1 receptor
  • MC1R melanocortin 1 receptor
  • MC1R When activated by one of the variants of MSH, typically -MSH, MC1R initiates a complex signaling cascade that leads to the production of the brown or black pigment eumelanin. These lead to a decrease of the formation of Tyrosinase - the most important enzyme forming melanin form tyrosine - about 20%.
  • TRP-2 tyrosinase related protein-2
  • the coffee oil prepared by present invention is applicable to skin whitening agent for cosmetic industry.
  • the coffee oil is also applicable to food industry especially in the area of beauty foods.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne de l'huile de café extraite par dioxyde de carbone supercritique qui se révèle utile pour le blanchiment de la peau par inhibition de la mélanogenèse. Une dose efficace d'huile de café, ladite dose étant de 10 mg/l d'huile de traitement, permet de réduire le taux total de mélanine de plus de 25 %. L'huile de café inhibe la période précoce de la mélanogenèse, ce qui a été prouvé par la régulation négative de 8 protéines identifiées, dont -MSH, MC1R, ACTHR, MITF, PKC-, SCF, TYR et TRP-2.
PCT/KR2012/008909 2012-10-29 2012-10-29 Inhibition de la mélanogenèse par l'huile de café extraite par co2 supercritique Ceased WO2014069677A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/KR2012/008909 WO2014069677A1 (fr) 2012-10-29 2012-10-29 Inhibition de la mélanogenèse par l'huile de café extraite par co2 supercritique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2012/008909 WO2014069677A1 (fr) 2012-10-29 2012-10-29 Inhibition de la mélanogenèse par l'huile de café extraite par co2 supercritique

Publications (1)

Publication Number Publication Date
WO2014069677A1 true WO2014069677A1 (fr) 2014-05-08

Family

ID=50627568

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/008909 Ceased WO2014069677A1 (fr) 2012-10-29 2012-10-29 Inhibition de la mélanogenèse par l'huile de café extraite par co2 supercritique

Country Status (1)

Country Link
WO (1) WO2014069677A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060018986A1 (en) * 2002-12-13 2006-01-26 L'oreal Extracts of decaffeinated coffee beans and orally administrable compositions comprised thereof for stimulating the sebaceous function of the skin
KR20070015569A (ko) * 2004-04-08 2007-02-05 브이디에프 퓨쳐슈티컬스, 인코포레이티드 커피 체리 화장품 조성물 및 방법
KR20110077722A (ko) * 2009-12-30 2011-07-07 (주)엔엘피 커피 찌꺼기를 이용한 유용성 추출물 및 그 제조방법
WO2012013764A2 (fr) * 2010-07-30 2012-02-02 Nestec S.A. Utilisation de grains de café torréfiés pour réguler la pigmentation de la peau

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060018986A1 (en) * 2002-12-13 2006-01-26 L'oreal Extracts of decaffeinated coffee beans and orally administrable compositions comprised thereof for stimulating the sebaceous function of the skin
KR20070015569A (ko) * 2004-04-08 2007-02-05 브이디에프 퓨쳐슈티컬스, 인코포레이티드 커피 체리 화장품 조성물 및 방법
KR20110077722A (ko) * 2009-12-30 2011-07-07 (주)엔엘피 커피 찌꺼기를 이용한 유용성 추출물 및 그 제조방법
WO2012013764A2 (fr) * 2010-07-30 2012-02-02 Nestec S.A. Utilisation de grains de café torréfiés pour réguler la pigmentation de la peau

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEE, J. H.: "Studies on Enhancement of Coffee Flavors and Efficacy by Supercritical Carbon Dioxide", THESIS OF GRADUATE SCHOOL OF AJOU UNIVERSITY, 2008, pages 1, 4, 7, 9, 10, 35 - 46 *
PARK, K. S.: "The Study of Cosmeceutical Activities from Coffee Beans and Application of MLV Liposomes on Advanced Formulation", THESIS OF GRADUATE SCHOOL OF DAEGU HAANNY UNIVERSITY, 2010, pages 47 - 58 *

Similar Documents

Publication Publication Date Title
CN109893463A (zh) 一种美白多肽组合物及其制备和用途
CN105267268B (zh) 人参叶提取物制造方法及包含其为有效成分的化妆品组合物
KR20190074880A (ko) 유용성분의 파괴가 적은 아세로라 열매 추출물의 제조방법 및 이 추출물을 함유하는 화장료 조성물
Wang et al. Review on oral plant extracts in Skin Whitening
Kim et al. Beauty food activities of wild-cultivated ginseng (Panax ginseng CA Meyer) ground part
WO2014069677A1 (fr) Inhibition de la mélanogenèse par l'huile de café extraite par co2 supercritique
KR20160137900A (ko) 인삼잎추출물 제조방법 및 이를 유효성분으로 함유하는 화장료 조성물
US10980736B2 (en) Coconut shell extracts, compositions containing same and uses
US20240130957A1 (en) Extracts of isochrysis species/tisochrysis species
Songtavisin et al. Azadirachta indica (Neem) water leaf extract inhibits melanin production and tyrosinase activity in B16F10 melanoma cells
KR102063940B1 (ko) 녹나무 성분을 함유하는 기능성 화장료 조성물 및 이의 제조 방법
KR102236023B1 (ko) 백서향 추출물을 유효성분으로 포함하는 주름 개선 또는 피부 미백용 조성물
KR101003470B1 (ko) 고대미 추출물을 함유하는 항산화용 화장료 조성물
KR101949271B1 (ko) 녹차 추출 펩타이드, 이의 제조방법 및 이를 함유하는 조성물
KR102128977B1 (ko) 흰꽃여뀌 추출물을 이용한 피부 주름 개선 및 피부 미백용 조성물
KR20160137466A (ko) 미백과 주름개선에 효과가 있는 천연식물 추출물 함유하는 화장품 조성물
KR101648477B1 (ko) 다크서클 개선 및 예방용 화장료 조성물
Sung et al. Skin whitening activity of supercritical fluid extract from spent coffee in B16F10 melanoma cell
KR102437871B1 (ko) 볶음 처리한 무말랭이 추출물을 함유하는 피부주름 개선 또는 피부노화 예방용 조성물 및 그 조성물을 포함하는 건강기능식품
KR20220077075A (ko) 칡 잎 추출물을 이용한 피부 미백과 피부 주름 개선용 조성물
EP3318246A1 (fr) Composition cosmétique éclaircissante comprenant un extrait de racine decaragana sinica
CA3119505A1 (fr) Extrait d'ecorce de pin blanc permettant de diminuer la secretion de l'endotheline-1, la synthese du facteur des cellules souches et la carbonylation des proteines
KR101274606B1 (ko) 초고압 대추 추출물을 함유하는 화장료 조성물
KR100935329B1 (ko) 엘라직산을 유효성분으로 포함하는 피부 미백활성을 갖는 장딸기의 열매 추출물
Kim et al. Inhibitory activity of ethyl acetate fraction derived from Cannabis sativaL. seed on melanogenesis in B16F10 cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12887543

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12887543

Country of ref document: EP

Kind code of ref document: A1